Hani Z. Asfour
Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah21589, Saudi Arabia
Tarek S. Ibrahim
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
Osama A. A. Ahmed
Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
Nabil A. Alhakamy
Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
Usama A. Fahmy
Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
LiveDNA: 20.22973
Mohammed W. Al-Rabia
Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah21589, Saudi Arabia
PDF Fulltext XML References Citation
How to cite this article
Hani Z. Asfour, Tarek S. Ibrahim, Osama A. A. Ahmed, Nabil A. Alhakamy, Usama A. Fahmy and Mohammed W. Al-Rabia, 2022. Sitagliptin Combined HIV-TAT as Potential Therapeutic Targeting of SARS-CoV-2 Virus. International Journal of Pharmacology, 18: 70-78.
DOI: 10.3923/ijp.2022.70.78
URL: https://scialert.net/abstract/?doi=ijp.2022.70.78
DOI: 10.3923/ijp.2022.70.78
URL: https://scialert.net/abstract/?doi=ijp.2022.70.78